Ontology highlight
ABSTRACT:
PROVIDER: PRJNA670615 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR12876200_1.fastq.gz | Fastqsanger.gz | |||
| SRR12876200_2.fastq.gz | Fastqsanger.gz | |||
| SRR12876300_1.fastq.gz | Fastqsanger.gz | |||
| SRR12876300_2.fastq.gz | Fastqsanger.gz | |||
| SRR12876201_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 384 |
Similar Datasets
Project description:Small cell lung carcinoma (SCLC) is a lethal neuroendocrine type of lung cancer with limited therapeutic options. We used single cell RNA sequencing (scRNA-seq) to study SCLC tumogenesis.
2023-08-08 | GSE218544 | GEO
Project description:The identification and characterisation of Circulating Tumour Cells (CTCs) is important to get insights into the biology of metastatic cancers, monitoring disease progression, and potential use in liquid biopsy-based personalised cancer treatment. The major limitation of CTC isolation is due to their heterogeneous nature, altered phenotype from primary tumour and availability in limited numbers. In the past years, several techniques have been developed to detect CTCs from peripheral blood, based on canonical markers. These methods are, however, prone to miss a larger set of CTCs due to variable or no expression of these markers. Furthermore, CTC enrichment processes are not free from White Blood Cell (WBC) contamination. Single cell RNA sequencing (scRNA-Seq) of CTCs provides a wealth of information about their tumors of origin as well as their fate. The first and most important roadblock encountered in CTC scRNA-Seq data analysis is confirmation of CTC capture. We present unCTC, an R software for unsupervised and semi-supervised characterisation of CTC transcriptomes, in contrast with WBCs. unCTC features various standard and novel computational/statistical modules for clustering, Copy Number Variation (CNV) inference, and marker based verification of the malignant phenotypes. Notably, we propose Deep Dictionary Learning using K-means clustering cost (DDLK) that robustly clusters scRNA-Seq profiles of CTCs and WBC contaminates to characterise heterogeneity among the concerned cell population. Interestingly, DDLK performs better as gene expression data is transformed into pathway enrichment profiles. To demonstrate the utility of unCTC, we produce scRNA-Seq profiles of breast CTCs enriched by the integrated ClearCell® FX/PolarisTM workflow that works on the principles of size selection and negative enrichment for CD45, a pan leukocyte marker.
2022-11-09 | GSE210651 | GEO
Project description:The identification and characterisation of Circulating Tumour Cells (CTCs) is important to get insights into the biology of metastatic cancers, monitoring disease progression, and potential use in liquid biopsy-based personalised cancer treatment. The major limitation of CTC isolation is due to their heterogeneous nature, altered phenotype from primary tumour and availability in limited numbers. In the past years, several techniques have been developed to detect CTCs from peripheral blood, based on canonical markers. These methods are, however, prone to miss a larger set of CTCs due to variable or no expression of these markers. Furthermore, CTC enrichment processes are not free from White Blood Cell (WBC) contamination. Single cell RNA sequencing (scRNA-Seq) of CTCs provides a wealth of information about their tumors of origin as well as their fate. The first and most important roadblock encountered in CTC scRNA-Seq data analysis is confirmation of CTC capture. We present unCTC, an R software for unsupervised and semi-supervised characterisation of CTC transcriptomes, in contrast with WBCs. unCTC features various standard and novel computational/statistical modules for clustering, Copy Number Variation (CNV) inference, and marker based verification of the malignant phenotypes. Notably, we propose Deep Dictionary Learning using K-means clustering cost (DDLK) that robustly clusters scRNA-Seq profiles of CTCs and WBC contaminates to characterise heterogeneity among the concerned cell population. Interestingly, DDLK performs better as gene expression data is transformed into pathway enrichment profiles. To demonstrate the utility of unCTC, we produce scRNA-Seq profiles of breast CTCs enriched by the integrated ClearCell® FX/PolarisTM workflow that works on the principles of size selection and negative enrichment for CD45, a pan leukocyte marker.
2024-12-31 | GSE181219 | GEO
Project description:The identification and characterisation of Circulating Tumour Cells (CTCs) is important to get insights into the biology of metastatic cancers, monitoring disease progression, and potential use in liquid biopsy-based personalised cancer treatment. The major limitation of CTC isolation is due to their heterogeneous nature, altered phenotype from primary tumour and availability in limited numbers. In the past years, several techniques have been developed to detect CTCs from peripheral blood, based on canonical markers. These methods are, however, prone to miss a larger set of CTCs due to variable or no expression of these markers. Furthermore, CTC enrichment processes are not free from White Blood Cell (WBC) contamination. Single cell RNA sequencing (scRNA-Seq) of CTCs provides a wealth of information about their tumors of origin as well as their fate. The first and most important roadblock encountered in CTC scRNA-Seq data analysis is confirmation of CTC capture. We present unCTC, an R software for unsupervised and semi-supervised characterisation of CTC transcriptomes, in contrast with WBCs. unCTC features various standard and novel computational/statistical modules for clustering, Copy Number Variation (CNV) inference, and marker based verification of the malignant phenotypes. Notably, we propose Deep Dictionary Learning using K-means clustering cost (DDLK) that robustly clusters scRNA-Seq profiles of CTCs and WBC contaminates to characterise heterogeneity among the concerned cell population. Interestingly, DDLK performs better as gene expression data is transformed into pathway enrichment profiles. To demonstrate the utility of unCTC, we produce scRNA-Seq profiles of breast CTCs enriched by the integrated ClearCell® FX/PolarisTM workflow that works on the principles of size selection and negative enrichment for CD45, a pan leukocyte marker.
2022-11-09 | GSE186288 | GEO
Project description:Small cell lung cancer (SCLC) is a particularly aggressive, lethal and widely metastatic lung cancer. Surgical specimens of SCLC are rare and difficult to obtain due to their early metastasis. In this study, we generated single cell lung suspensions of SCLC tissues. ScRNA-seq was performed on CD45 and CD31 negative live cells sorted by FACS. Purified cells were clustered to evaluate the cancer cell sub-clusters.
2022-12-18 | GSE164404 | GEO
Project description:Transforming growth factor (TGF)-beta induces apoptosis of many types of cancer cells and acts as a tumor suppressor. We found lower expression of TGF-beta type II receptor (TbRII) in most of SCLC cells and tissues than in normal lung epithelial cells and normal lung tissues, respectively. In vitro cell growth and in vivo tumor formation were suppressed by TGF-beta-mediated apoptosis when the wild-type TbRII was overexpressed in SCLC cells. We therefore determined Smad2 and Smad3 (Smad2/3) binding sites in a SCLC cell line H345 stably expressing exogenous TbRII (H345-TbRII) to identify target genes of TGF-beta. Smad2 and Smad3 binding sites in H345-TbRII cells were determined by ChIP-seq (one sample analysis, without replicates).
2015-09-15 | E-GEOD-63871 | biostudies-arrayexpress
Project description:Circulating Tumor Cells (CTCs) are shed from primary tumors into the bloodstream, mediating the hematogenous spread of cancer to distant organs. Using a pancreatic cancer mouse model, we applied a microfluidic device to isolate CTCs independently of tumor epitopes, subjecting these to single cell RNA-sequencing. This study was conducted to determine the heterogeneity of pancreatic CTCs and to compare these CTCs to matched primary tumors, cell line controls (NB508 cancer cell line and MEF non-cancer cell line), primary tumor single cells, and normal leukocytes/WBCs.
2014-09-22 | GSE51372 | GEO
Project description:Pancreatic cancer is a complex disease with a desmoplastic stroma, extreme hypoxia, and inherent resistance to therapy. Understanding the signaling and adaptive response of such an aggressive cancer is key to making advances in therapeutic efficacy and understanding disease progression. Redox factor-1 (Ref-1), a redox signaling protein, regulates the DNA binding activity of several transcription factors, including HIF-1. The conversion of HIF-1 from an oxidized to reduced state leads to enhancement of its DNA binding. In our previously published work, knockdown of Ref-1 under normoxia resulted in altered gene expression patterns on pathways including EIF2, protein kinase A, and mTOR. In this study, single cell RNA sequencing (scRNA-seq) and proteomics were used to explore the effects of Ref-1 on metabolic pathways under hypoxia.Results: We also integrated the scRNA data analysis with the proteomic analysis and found that the differentially expressed genes and pathways identified from the scRNA-seq data are highly consistent to the significant proteins observed in the proteomics data, especially for the upregulated cell cycle and transcription pathways and downregulated metabolic, apoptosis and signaling pathways under hypoxia. Conclusion: The scRNA-seq and proteomics data consistently demonstrated down-regulated central metabolism pathways in APE1/Ref-1 knockdown vs scrambled control under both normoxia and hypoxia conditions. Experimental Methods: scRNA-seq comparing pancreatic cancer cells expressing less than 20% of the Ref-1 protein was analyzed using left truncated mixture Gaussian model. Matched samples were also collected for bulk proteomic analysis of the four conditions. scRNA-seq data was validated using proteomics and qRT-PCR. Ref-1’s role in mitochondrial function was confirmed using mitochondrial function assays and qRT-PCR. Results: We also integrated the scRNA data analysis with the proteomic analysis and found that the differentially expressed genes and pathways identified from the scRNA-seq data are highly consistent to the significant proteins observed in the proteomics data, especially for the upregulated cell cycle and transcription pathways and downregulated metabolic, apoptosis and signaling pathways under hypoxia. Conclusion: The scRNA-seq and proteomics data consistently demonstrated down-regulated central metabolism pathways in APE1/Ref-1 knockdown vs scrambled control under both normoxia and hypoxia conditions.
2021-09-09 | PXD020515 | Pride